A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease

Neurobiology of Aging

Volumn 37, Issue , 2016, Pages 103-116

  Choong, Chi Jing ^a   Sasaki, Tsutomu ^a   Hayakawa, Hideki ^a   Yasuda, Toru ^b   Baba, Kousuke ^a   Hirata, Yoshiyuki ^c   Uesato, Shinichi ^c   Mochizuki, Hideki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c KANSAI UNIVERSITY   (Japan)

Author keywords

Histone deacetylase; Histone deacetylase inhibitor; Isoform specific; K560; MPTP; Neurodegeneration; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; K 560; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEUROPROTECTIVE AGENT; PROTEIN P53; PUMA PROTEIN; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE; ISOENZYME; K560 COMPOUND; PIPERAZINEDIONE; XIAP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL PARKINSONISM; HUMAN; HUMAN CELL; IC50; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA PARS COMPACTA; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE;

ACETYLATION; ADMINISTRATION, ORAL; ANIMALS; BENZAMIDES; CELL DEATH; CELL LINE, TUMOR; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENE EXPRESSION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONES; HUMANS; ISOENZYMES; MICE; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84953259927     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.10.001     Document Type: Article

References (67)

1. Bardai, F.H., D'Mello, S.R., Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J. Neurosci. 31 (2011), 1746–1751.
2. Bardai, F.H., Price, V., Zaayman, M., Wang, L., D'Mello, S.R., Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J. Biol. Chem. 287 (2012), 35444–35453.
3. Bardai, F.H., Verma, P., Smith, C., Rawat, V., Wang, L., D'Mello, S.R., Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. J. Neurosci. 33 (2013), 11833–11838.
4. Bobrowska, A., Paganetti, P., Matthias, P., Bates, G.P., Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One, 6, 2011, e20696.
5. Chen, P.S., Peng, G., Li, G., Yang, S., Wu, X., Wang, C., Wilson, B., Lu, R.B., Gean, P.W., Chuang, D.M., Hong, J.S., Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006), 1116–1125.
6. Chen, P.S., Wang, C.-C., Bortner, C.D., Peng, G.-S., Wu, X., Pang, H., Lu, R.B., Gean, P.W., Chuang, D.M., Hong, J.S., Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007), 203–212.
7. Chen, S.H., Wu, H.M., Ossola, B., Schendzielorz, N., Wilson, B.C., Chu, C.H., Chen, S.L., Wang, Q., Zhang, D., Qian, L., Li, X., Hong, J.S., Lu, R.B., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol. 165 (2012), 494–505.
8. Chen, Y., He, R., Chen, Y., D'Annibale, M.A., Langley, B., Kozikowski, A.P., Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. Chem. Med. Chem. 4 (2009), 842–852.
9. Choi, H.K., Choi, Y., Kang, H., Lim, E.J., Park, S.Y., Lee, H.S., Park, J.M., Moon, J., Kim, Y.J., Choi, I., Joe, E.H., Choi, K.C., Yoon, H.G., PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death. Hum. Mol. Genet. 24 (2015), 1127–1141.
10. Choi, H.K., Choi, Y., Park, E.S., Park, S.Y., Lee, S.H., Seo, J., Jeong, M.H., Jeong, J.W., Jeong, J.H., Lee, P.C., Choi, K.C., Yoon, H.G., Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response. Nat. Commun., 6, 2015, 7390.
11. Collins, L.M., Adriaanse, L.J., Theratile, S.D., Hegarty, S.V., Sullivan, A.M., O'Keeffe, G.W., Class-iia histone deacetylase inhibition promotes the growth of Neural processes and protects them against neurotoxic insult. Mol. Neurobiol. 51 (2015), 1432–1442.
12. Crocker, S.J., Liston, P., Anisman, H., Lee, C.J., Smith, P.D., Earl, N., Thompson, C.S., Park, D.S., Korneluk, R.G., Robertson, G.S., Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiol. Dis. 12 (2003), 150–161.
13. Deveraux, Q.L., Takahashi, R., Salvesen, G.S., Reed, J.C., X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997), 300–304.
14. Du, G., Liu, X., Chen, X., Song, M., Yan, Y., Jiao, R., Wang, C.C., Drosophila histone deacetylase 6 protects dopaminergic neurons against α-synuclein toxicity by promoting inclusion formation. Mol. Biol. Cell 21 (2010), 2128–2137.
15. Du, Y., Wang, F., Zou, J., Le, W., Dong, Q., Wang, Z., Shen, F., Yu, L., Li, Y., Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response. Neurobiol. Aging 35 (2014), 2316–2328.
16. Eberhardt, O., Coelln, R.V., Kugler, S., Lindenau, J., Rathke-Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A., Bahr, M., Weller, M., Dichgans, J., Schulz, J.B., Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20 (2000), 9126–9134.
17. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A., Breslow, R., Pavletich, N.P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999), 188–193.
18. Furuya, T., Hayakawa, H., Yamada, M., Yoshimi, K., Hisahara, S., Miura, M., Mizuno, Y., Mochizuki, H., Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 24 (2004), 1865–1872.
19. Goers, J., Manning-Bog, A.B., McCormack, A.L., Millett, I.S., Doniach, S., Di Monte, D.A., Uversky, V.N., Fink, A.L., Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42 (2003), 8465–8471.
20. Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O.M., Bradke, F., Lu, J., Fischer, A., Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol. Med. 5 (2013), 52–63.
21. Graff, J., Rei, D., Guan, J.S., Wang, W.Y., Seo, J., Hennig, K.M., Nieland, T.J., Fass, D.M., Kao, P.F., Kahn, M., Su, S.C., Samiei, A., Joseph, N., Haggarty, S.J., Delalle, I., Tsai, L.H., An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483 (2012), 222–226.
22. Gregoretti, I.V., Lee, Y.M., Goodson, H.V., Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004), 17–31.
23. Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, J., Nieland, T.J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J.E., DePinho, R.A., Jaenisch, R., Tsai, L.H., HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009), 55–60.
24. Hagelkruys, A., Lagger, S., Krahmer, J., Leopoldi, A., Artaker, M., Pusch, O., Zezula, J., Weissmann, S., Xie, Y., Schöfer, C., Schlederer, M., Brosch, G., Matthias, P., Selfridge, J., Lassmann, H., Knoblich, J.A., Seiser, C., A single allele of Hdac2 but not Hdac1 is sufficient for normal mouse brain development in the absence of its paralog. Development 141 (2014), 604–616.
25. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S.L., Gottesfeld, J.M., Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2 (2006), 551–558.
26. Hirata, Y., Hirata, M., Kawaratani, Y., Shibano, M., Taniguchi, M., Yasuda, M., Ohmomo, Y., Nagaoka, Y., Baba, K., Uesato, S., Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. Bioorg. Med. Chem. Lett. 22 (2012), 1926–1930.
27. Jackson-Lewis, V., Przedborski, S., Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007), 141–151.
28. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A., Yao, T.P., The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003), 727–738.
29. Kelly, W.K., Richon, V.M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J.H., Rifkind, R., Marks, P.A., Scher, H., Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003), 3578–3588.
30. Kernochan, L.E., Russo, M.L., Woodling, N.S., Huynh, T.N., Avila, A.M., Fischbeck, K.H., Sumner, C.J., The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14 (2005), 1171–1182.
31. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S.C., Carey, N., Finn, P.W., Collins, L.S., Tumber, A., Ritchie, J.W., Jensen, P.B., Lichenstein, H.S., Sehested, M., Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008), 581–589.
32. +-mediated toxicity by histone deacetylase inhibition. Brain Res. 1354 (2010), 172–178.
33. Kidd, S.K., Schneider, J.S., Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 194 (2011), 189–194.
34. Kim, J.Y., Shen, S., Dietz, K., He, Y., Howell, O., Reynolds, R., Casaccia, P., HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13 (2010), 180–189.
35. Kontopoulos, E., Parvin, J.D., Feany, M.B., Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15 (2006), 3012–3023.
36. Korecka, J.A., van Kesteren, R.E., Blaas, E., Spitzer, S.O., Kamstra, J.H., Smit, A.B., Swaab, D.F., Verhaagen, J., Bossers, K., Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One, 8, 2013, e63862.
37. Langley, B., D'Annibale, M.A., Suh, K., Ayoub, I., Tolhurst, A., Bastan, B., Yang, L., Ko, B., Fisher, M., Cho, S., Beal, M.F., Ratan, R.R., Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 28 (2008), 163–176.
38. Lebrun-Julien, F., Suter, U., Combined HDAC1 and HDAC2 depletion promotes retinal ganglion cell survival after injury through reduction of p53 target gene expression. ASN Neuro., 7, 2015.
39. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M., Przedborski, S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999), 1403–1409.
40. Mochizuki, H., Hayakawa, H., Migita, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo-Nakanishi, Y., Urabe, T., Yamada, M., Tamayose, K., Shimada, T., Miura, M., Mizuno, Y., An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 10918–10923.
41. Monti, B., Gatta, V., Piretti, F., Raffaelli, S.S., Virgili, M., Contestabile, A., Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 17 (2010), 130–141.
42. Moumné, L., Campbell, K., Howland, D., Ouyang, Y., Bates, G.P., Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS One, 7, 2012, e31080.
43. Norwood, J., Franklin, J.M., Sharma, D., D'Mello, S.R., Histone deacetylase 3 is necessary for proper brain development. J. Biol. Chem. 289 (2014), 34569–34582.
44. Nutt, J., Williams, A., Plotkin, C., Eng, N., Ziegler, M., Calne, D.B., Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations. Can J. Neurol. Sci. 6 (1979), 337–343.
45. Olson, D.E., Sleiman, S.F., Bourassa, M.W., Wagner, F.F., Gale, J.P., Zhang, Y.L., Ratan, R.R., Holson, E.B., Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism. Chem. Biol. 22 (2015), 439–445.
46. Peng, S., Zhao, S., Yan, F., Cheng, J., Huang, L., Chen, H., Liu, Q., Ji, X., Yuan, Z., HDAC2 Selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. J. Neurosci. 35 (2015), 1250–1259.
47. Rouaux, C., Jokic, N., Mbebi, C., Boutillier, S., Loeffler, J.P., Boutillier, A.L., Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22 (2003), 6537–6549.
48. Sadri-Vakili, G., Bouzou, B., Benn, C.L., Kim, M.O., Chawla, P., Overland, R.P., Glajch, K.E., Xia, E., Qiu, Z., Hersch, S.M., Clark, T.W., Yohrling, G.J., Cha, J.H., Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16 (2007), 1293–1306.
49. Shan, B., Xu, C., Zhang, Y., Xu, T., Gottesfeld, J.M., Yates, J.R. 3rd, Quantitative proteomic analysis identifies targets and pathways of a 2-aminobenzamide HDAC inhibitor in Friedreich's ataxia patient iPSC-derived neural stem cells. J. Proteome Res. 13 (2014), 4558–4566.
50. Simonini, M.V., Camargo, L.M., Dong, E., Maloku, E., Veldic, M., Costa, E., Guidotti, A., The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 103 (2005), 1587–1592.
51. Sleiman, S.F., Olson, D.E., Bourassa, M.W., Karuppagounder, S.S., Zhang, Y.L., Gale, J., Wagner, F.F., Basso, M., Coppola, G., Pinto, J.T., Holson, E.B., Ratan, R.R., Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition. J. Neurosci. 34 (2014), 14328–14337.
52. Su, M., Shi, J.J., Yang, Y.P., Li, J., Zhang, Y.L., Chen, J., Hu, L.F., Liu, C.F., HDAC6 regulates aggresome-autophagy degradation pathway of α-synuclein in response to MPP+-induced stress. J. Neurochem. 117 (2011), 112–120.
53. Suzuki, T., Ando, T., Tsuchiya, T., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., Nakanishi, O., Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42 (1999), 3001–3003.
54. Taes, I., Timmers, M., Hersmus, N., Bento-Abreu, A., Van Den Bosch, L., Van Damme, P., Auwerx, J., Robberecht, W., Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 22 (2013), 1783–1790.
55. Tsang, A.H., Lee, Y.I., Ko, H.S., Savitt, J.M., Pletnikova, O., Troncoso, J.C., Dawson, V.L., Dawson, T.M., Chung, K.K., S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 4900–4905.
56. Venkatraman, A., Hu, Y.S., Didonna, A., Cvetanovic, M., Krbanjevic, A., Bilesimo, P., Opal, P., The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1. Hum. Mol. Genet. 23 (2014), 3733–3745.
57. Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S.J., Przedborski, S., Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 2837–2842.
58. Wang, C., Luan, Z., Yang, Y., Wang, Z., Cui, Y., Gu, G., Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-α from activated astrocytes. Neurosci. Lett. 497 (2011), 122–127.
59. Wang, Y., Wang, X., Liu, L., Wang, X., HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett. 467 (2009), 212–216.
60. Waterborg, J.H., Dynamics of histone acetylation in vivo. A function for acetylation turnover?. Biochem. Cell Biol. 80 (2002), 363–378.
61. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H., Przedborski, S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002), 1763–1771.
62. Wu, X., Chen, P.S., Dallas, S., Wilson, B., Block, M.L., Wang, C.-C., Kinyamu, H., Lu, N., Gao, X., Leng, Y., Chuang, D.M., Zhang, W., Lu, R.B., Hong, J.S., Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11 (2008), 1123–1134.
63. Yasuda, T., Hayakawa, H., Nihira, T., Ren, Y.R., Nakata, Y., Nagai, M., Hattori, N., Miyake, K., Takada, M., Shimada, T., Mizuno, Y., Mochizuki, H., Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 70 (2011), 686–697.
64. Yoshida, M., Horinouchi, S., Beppu, T., Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17 (1995), 423–430.
65. Yoshida, M., Kijima, M., Akita, M., Beppu, T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990), 17174–17179.
66. + toxicity: dual roles for ERK1/2. Cell Death Dis., 3, 2012, e312.
67. Zhuang, S., Schnellmann, R.G., A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319 (2006), 991–997.